Structural Heart Occlusion Portfolio

AMPLATZER™ Muscular VSD Occluder next to AMPLATZER™ Amulet™ Left Atrial Appendage Occluder

Portfolio Overview

  • Minimally invasive transcatheter closure of heart defects
  • Designed for conformability and complete closure
  • Built on proven AMPLATZER™ technology

A Comprehensive Portfolio

We offer a broad portfolio of structural heart occluders designed to treat some of the most common congenital heart defects and for reducing the risk of stroke. 

Mother smiling and holding a happy infant

Congenital Heart Defects

Congenital heart defects occur in around 8 per 1,000 births6—25 percent of babies born with a congenital heart defect require some form of invasive treatment within the first year.7

A leader in pediatric cardiology and the treatment of congenital heart defects, St. Jude Medical offers technology for minimally invasive, transcatheter closure of some of the most common congenital heart defects:

Atrial septal defects (ASD)
Ventricular septal defects (VSD)
Patent ductus arteriosus (PDA)

Reducing Stroke Risk

Heart defects may increase the risk for developing other medical complications.

Current evidence suggests that percutaneous occlusion of the left atrial appendage (LAA) or patent foramen ovale (PFO) may reduce the risk of thromboembolic complications in some patients.8-11

We offer devices specifically designed to occlude the left atrial appendage (LAA) and the patent foramen ovale (PFO) for stroke prevention.

Drawing of catheter-based AMPLATZER™ structural heart occluder inside human heart
Drawing of the heart that shows areas affected by structural heart defects

Transforming the Treatment of Structural Heart Disease

More than 71,000 children in the U.S. and European Union combined are born with structural heart defects each year.12,13 St. Jude Medical offers surgical and transcatheter options for treating structural heart disease. We are focused on improving the lives of patients and offering physicians like you products designed for ease of use and that have proven clinical outcomes.2,14

Learn more about our approach to structural heart disease.


1. St. Jude Medical. (2014, December). AMPLATZER™ Septal Occluder Instructions for Use.
2. Forbes T. (2011, July). Interim results of the Amplatzer septal occluder post approval study. Presented at the meeting of the Pediatric and Adult Interventional Cardiac Symposium, Boston, MA.
3. Everett, A. D., Jennings, J., Sibinga, E., Owada, C., Lim, D. S., Cheatham, J., ... Ringel, R. (2009).
Community use of the Amplatzer atrial septal defect occluder: Results of the multicenter MAGIC atrial septal defect study. Pediatric Cardiology, 30(3), 240-247.
4. Chatterjee, T., Petzsch, M., Ince, H., Rehders, T. C., Körber, T., Weber, F., … Nienaber, C. A. (2005). Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. Journal of Interventional Cardiology, 18(3), 173-179.
5. St. Jude Medical. Data on file, number of implants as of March 2011.
6. Bernier, P. L., Stefanescu, A., Samoukovic, G., & Tchervenkov, C. I. (2010). The challenge of congenital heart disease worldwide: Epidemiologic and demographic facts. Seminars in Thoracic and Cardiovascular Surgery, Pediatric Cardiac Surgery Annual, 13, 26-34.
7. Oster, M. E., Lee, K. A., Honein, M. A., Riehle-Colarusso, T., Shin, M., & Correa, A. (2013, May). Temporal trends in survival among infants with critical congenital heart defects. Pediatrics, 131(5), e1502-e1508.
8. National Institute for Health and Clinical Excellence (NICE). (2010, June). Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. In NICE Interventional Procedure Guide (349). Retrieved from
9. Kent, D. & Thaler, D. (2010). Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke, 41(10 Suppl.), S26-S30.
10. Homma, S. & Sacco, R. (2007). Patent foramen ovale and stroke. Circulation, 112(7), 1063-1072.
11. Handke, M., Harloff, A., Olschewski, M., Hetzel, A., & Geibel, A. (2007). Patent foramen ovale and cryptogenic stroke in older patients. The New England Journal of Medicine, 357(22), 2262-2268.
12. National Institutes of Health. What are congenital heart defects? Retrieved from
13. Dolk, H., Loane, M., Game, E., & European Surveillance of Congenital Anomalies (EUROCAT) Working Group. (2011). Congenital heart defects in Europe: Prevalence and perinatal mortality, 2000 to 2005. Circulation, 123(8), 841-849.
14. Bavaria, J. E., Desai, N. D., Cheung, A., Petracek, M. R., Groh, M. A., Borger, M. A., & Schaff, H. V. (2014). The St. Jude Medical Trifecta aortic pericardial valve: Results from the global, multicenter, prospective clinical study. Journal of Thoracic and Cardiovascular Surgery, 147(2), 590-597.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.